98 studies found for:    heart block | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Galectin-3 Blockade in Patients With High Blood Pressure
Condition: Hypertension
Intervention: Dietary Supplement: Modified Citrus Pectin (MCP)
22 Recruiting Effect of Fasting on the Asthma Inflammasome
Condition: Asthma
Intervention:
23 Recruiting Longitudinal Observational Study of Severe Asthma
Condition: Asthma
Intervention:
24 Recruiting Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: quality-of-life assessment
25 Recruiting Randomized Controlled Trial of Group Prevention Coaching
Condition: Cardiovascular Disease
Intervention: Behavioral: Problem Solving
26 Recruiting Randomized Endo-Vein Graft Prospective
Condition: Coronary Artery Bypass Grafting
Intervention: Procedure: Vein Harvesting Procedures
27 Recruiting Antibody Treatment for Advanced Celiac Disease
Conditions: Celiac Disease;   Celiac Sprue;   Gluten Enteropathy;   Gluten-Sensitive Enteropathy
Intervention: Biological: Hu-Mik- Beta-1
28 Recruiting Lidocaine For Neuroprotection During Cardiac Surgery
Condition: Cognitive Decline
Interventions: Drug: Lidocaine;   Drug: Placebo
29 Recruiting Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Conditions: Oxidative Stress;   Endothelial Dysfunction
Interventions: Drug: ramipril (ACE inhibitor);   Drug: valsartan (ARB);   Drug: Placebo
30 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
31 Recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions: Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
32 Recruiting Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access
Condition: Aortic Valve Stenosis
Intervention: Procedure: CA-TAVR
33 Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Drug: pemetrexed disodium
34 Recruiting Natural History of Sickle Cell Disease and Other Hemolytic Disorders
Conditions: Hemoglobin SC Disease;   Hematologic Diseases;   Sickle Cell Anemia;   Hemolytic Anemia
Intervention:
35 Recruiting Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Condition: Healthy Subjects
Intervention:
36 Recruiting PAHTCH (Carvedilol)
Condition: Pulmonary Hypertension
Interventions: Drug: Carvedilol;   Drug: Carvedilol placebo
37 Recruiting Validation of Coronary Calcium Subtraction to Improve Diagnostic Accuracy of Coronary CT Angiography
Condition: Coronary Artery Disease
Intervention:
38 Recruiting Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Interventions: Drug: albuterol inhaler;   Procedure: PFT;   Drug: albuterol nebulizer
39 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
40 Recruiting Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer
Conditions: Carcinoma of Unknown Primary Origin;   Extensive Stage Small Cell Lung Carcinoma;   Large Cell Lung Carcinoma;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary Origin;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Veliparib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years